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ABSTRACT
Background: Sphingosine-1-phosphate (S1P), a lysophospholipid released from inflammatory cells, causes
cell migration by increasing cytokines and chemokines. This study was designed to determine whether S1P
causes adherence of eosinophils to pulmonary endothelial cells via enhancement of adhesion molecule ex-
pression.
Methods: Expression of VCAM-1 and ICAM-1 was assessed by RT-PCR and Western blot analysis in human
pulmonary microvasucular endothelial cells (HPMVECs). The number of adherent eosinophils to HPMVECs
was calculated according to adhesion assay.
Results: Pre-treatment of HPMVECs with S1P increased mRNA and protein expression of VCAM-1, in con-
trast, did not dramatically increase those expression of ICAM-1. The maximal expression of these adhesion
molecules in mRNA and protein was observed 4 and 8 h after exposure to S1P, respectively. Pre-treatment
with S1P also activated RhoA, a monomeric G protein; the ability of S1P to enhance the expression of VCAM-1
was attenuated by RhoA related inhibitors such as Y-27632, C3 exoenzyme, and GGTI-286. The effects of S1P
on VCAM-1 were attenuated by pre-incubation with pertussis toxin, which catalyzes the ADP-ribosylation of Gi,
a heterotrimeric G protein.
After HPMVECs were treated with S1P, adhesion of human eosinophilic leukemic cell line (EoL-1) cells to
HPMVECs was enhanced in a concentration-dependent manner. Augmented adherence of EoL-1 cells by S1P
was also attenuated by Y-27632 and pertussis toxin. S1P causes adherence of eosinophils to pulmonary endo-
thelium via RhoA activation.
Conclusions: S1P may act as a lipid mediator in asthma. The RhoARho-kinase pathway may be a thera-
peutic target for preventing eosinophil infiltration to the airway.
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INTRODUCTION
Sphingosine 1-phosphate (S1P), a bioactive lysophos-
pholipid generated in the plasma membrane, is capa-
ble of wide spectrum of biological effects, including
cell growth, cell differentiation, and cell migration.1 A
clinical trial has demonstrated that the level of S1P is
elevated in bronchoalveolar lavage (BAL) fluid from
patients with asthma following allergen challenges.2
S1P causes eosinophil recruitment,3,4 contraction of
airway smooth muscle,5 augmented responsiveness
to methacholine,6,7 and cytokine production involving
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airway remodeling.2 Therefore, S1P may play an im-
portant role in the pathophysiology of asthma.8
Inhalation of lysophosphatidylcholine (Lyso-PC), a
lysophospholipid synthesized by phospholipase A2, to
guinea-pigs causes eosinophil recruitment to the air-
ways, similar to S1P.9 Lyso-PC enhances expression
of adhesion molecule such as vascular adhesion
molecule 1 (VCAM-1) and intracellular adhesion
molecule 1 (ICAM-1) in human and rabbit endothelial
cells.10 When S1P and Lyso-PC are released from in-
flammatory cells, these lysophospholipids may act as
novel lipid mediators in patients with asthma. How-
ever, little is currently known about mechanisms un-
derlying eosinophil recruitment induced by S1P in
detail.
Although cytokines and chemokines play an impor-
tant role in the eosinophil infiltration to the airways,
eosinophil adhesion to endothelial cells is a funda-
mental process for this phenomenon. Adhesion mole-
cules (VCAM-1 and ICAM-1) contribute to the
eosinophil recruitment from the circulation since acti-
vated endothelial cells transiently express adhesion
molecules involved in the trafficking of circulating in-
flammatory cells across the endothelial barrier into
underlying tissues.11 However, involvement of S1P in
the induction of the adhesion molecules remains to
be elucidated.
RhoA, a small monomeric GTP-binding (G) pro-
tein, and Rho-kinase, an effector molecule of RhoA,
have effects on Ca2+ sensitization, cell differentiation,
and cytoskeleton reorganization.12,13 Y-27632 and HA-
1077, Rho-kinase inhibitors, inhibit both eosinophilic
inflammation and airway hyperresponsiveness in-
duced allergen challenges in the airways.14 Y-27632
also inhibits agonist-induced contraction,5,15-17 β-
adrenergic desensitization,18,19 hyperresponsiveness
to methacholine,6,20 and cell proliferation21 in airway
smooth muscle. RhoA is proposed as one of the post-
receptor signal transduction pathways of S1P. There-
fore, relationship between S1P and the RhoARho-
kinase pathways may play a key role for the patho-
physiology of asthma.
This study was designed to determine whether S1P
is involved in the eosinophil inflammation of asthma.
We examined causal relationship between S1P and
expression of the adhesion molecules on the cell sur-
face in pulmonary endothelial cells. Moreover, intra-
cellular mechanisms of upregulation of the adhesion
molecules induced by S1P were investigated in detail,
focused on the RhoARho-kinase processes.
METHODS
CELL CULTURE
Normal human pulmonary microvascular endothelial
cells (HPMVECs) from multiple donors were ob-
tained from Cambrex (Walkersville, MD, USA). The
cells were maintained in culture medium (EBM-2;
Cambrex), containing 5% fatal bovine serum (FBS),
hydrocortisone, hEGF, hFGF-B, VEGF, R3-IGF-1,
gentamicin, amphotericinB and ascorbic acid (EGM-
2MV; Cambrex) in an atmosphere of 5% CO2 and 95%
air at 37℃. Cells at 5-8th passage were used for the
experiments. A human eosinophilic leukemic cell line
(EoL-1),22 which has been considered to be an in vi-
tro eosinophilic model, was obtained from RIKEN
BioResource Center (Tsukuba, Japan) and main-
tained in RPMI 1640 medium (Nissui Pharmaceuti-
cal, Tokyo, Japan) supplemented with 10% FBS, peni-
cillin and streptomycin.
RT-PCR
HPMVECs were sub-cultured in 60 mm dishes in
complete EBM-2 medium at a density of 1 × 105 cells
dish, then in a serum-starved EBM-2 medium for 24
h. Total RNA wad isolated after stimulation with S1P
using the RNeasy mini kit (Qiagen in Japan, Tokyo,
Japan) according to the manufacturer’s instructions.
RNA was reverse transcribed to cDNA using a Super-
script III kit (Invitrogen, Carlsbad, CA, USA). PCR
amplification was performed with 30 cycles of 30 s at
94℃, 30 s at 60℃, and 60 s at 72℃. Oligonucleotide
primers were generated by (Rikaken Co., Ltd., Na-
goya, Japan) using the following sequences: VCAM-1,
5’-TCCGTCTCATTGACTTGCAG-3’ and 5’-TTCCAG
G-GACTTCCTGTCTG-3’; ICAM-1, 5’-CATAGAGACC
CCGTTGCCTA-3’ and 5’-GAA-ATTGGCTCCATGGT
GAT-3’; GAPDH 5’-AACGGATTTGGTCGTATTGG-3’
and 5’TGAGTCCTTCCACGATACCA-3’; very late an-
tigen 4 (VLA-4); 5’-GAGTGCCCC-CTGATTTACGA-3’
and 5’-TCCAACGAGGTTTGTTTCCA-3’; lymphocyte
function associated antigen 1 (LFA-1), 5’-GCTGGGG
GCTTTCTTGACCT-3’ and 5’-GCCTTG-GAACTGGG
GGATGA-3’. The product sizes were VCAM-1 407 bp,
ICAM-1 375 bp, GAPDH 498 bp, VLA-4 581 bp, and
LFA-1 876 bp. PCR products were resolved on 1.6%
agarose gels, stained with ethidium bromide, and
photographed. Quantification of RT-PCR were nor-
malized to GAPDH and analyzed by using digital
scanning and Scion Image software (Scion Image,
Frederick, MD, USA).
RhoA ACTIVATION ASSAY
RhoA activation was measured by Rhotekin pull-down
assay. HPMVECs were grown to confluence in 100
mm dishes and then placed in serum-free medium for
24 h. Cells were stimulated with 10 μM S1P for 10
min. After stimulation with S1P, cells were then
washed with ice cold PBS. The GTP-RhoA enriched
lysates was prepared using the Rho Activation Kit
(Upstate Biotechnology Inc, Lake Placid, NY, USA),
according to the manufacturer’s instructions.
WESTERN BLOTTING
Expression of VCAM-1, ICAM-1 and RhoA in
HPMVEC were evaluated by using specific antibod-
ies for each protein. HPMVECs were grown to con-
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fluence in 60-mm dishes and then placed in serum-
free medium for 24 h. Cells were stimulated with a
range of concentrations (0.1-10 μM) of S1P for vari-
ous times (0-24 h). After stimulation with S1P, cells
were washed with ice-cold PBS. Whole cellular
lysates were prepared with lysis buffer (50 mM Tris-
HCl [pH 6.8], 10% glycerol, 2% SDS, 5% 2-
mercaptoethanol). Protein contents of cellular lysates
were measured by using Bio-Rad protein assay re-
agent kit (Bio-Rad, Hercules, CA, USA). Equal
amounts of lysates, adjusted to protein content, were
resolved by SDS-PAGE using a 4-20% linear gradient
running gel (Daiichi Pure Chemicals, Tokyo, Japan).
Proteins were transferred to nitrocellulose mem-
brane, and the membrane was incubated at room
temperature in PBS for 1 h. Immunoblotting was per-
formed using antibodies against VCAM-1 (sc-8304;
Santa Cruz Biotechnology, Santa Cruz, CA, USA),
ICAM-1 (sc-1511; Santa Cruz Biotechnology) and
RhoA (RhoA [26C4]: sc-418; Santa Cruz Biotechnol-
ogy). Immunodetection was accomplished using a
donkey anti-rabbit secondary antibody or a rabbit
anti-goat secondary antibody and the enhanced
chemiluminescence kit (Amersham Biosciences, Pis-
cataway, NJ, USA). The intensity was quantified by
using Scion image software (Scion Image).
EoL-1 ADHESION ASSAY
The adhesion assays were performed as previously
described with modifications.23 HPMVECs were
grown to confluence in 24-well plates in complete
EBM-2 medium. Cells were stimulated with 1 or 10
μM S1P for 6 h in complete medium. For experi-
ments using inhibitors, 10 μM Y-27632 or 300 ngml
Pertussis toxin (PTX) were applied 30 min or 4 h be-
fore the stimulation, respectively. Before addition of
human eosinophilic leukemic cells, EoL-1 cells to the
endothelial cells, EoL-1 cells (1 × 106 cellsml) were
labeled for 40 min at 37℃ with 5 μM of fluorescence
dye calcein acetomethylester (Calcein-AM; Dojindo
Laboratories, Kumamoto, Japan) in RPMI1640 me-
dium containing 10% FBS. EoL-1 cells were then
washed two times with, and resuspended in RPMI
1640 medium containing 10% FBS (final concentra-
tion, 1 × 106 cellsml). A 1 ml aliquot of the stained
cell suspension (1 × 106 cellswell) was added to the
endothelial cells in 24-well plates from which the me-
dium containing S1P and inhibitors were removed.
The plates were incubated for 1 h at 37℃, and then
washed two times with RPMI1640, and PBS (1 ml
well) was added. The relative fluorescence was meas-
ured using a fluorescence microplate reader
(Fluoroskan Ascent CF; Labsystems, Helsinki, Fin-
land), with excitation and emission wavelengths of
485 and 538 nm, respectively. The number of EoL-1
cells adhered to HPMVECs was calculated by com-
paring fluorescence to standard curves of Calcein-AM
activitycell.
EXPERIMENTAL PROTOCOLS
To determine the effects of S1P on adhesion mole-
cules in HPMVECs, expression of VCAM-1 and
ICAM-1 in response to S1P was examined using RT-
PCR and Western blots. To determine whether the
RhoA signal transduction pathways are involved in
the upregulation of VCAM-1 and ICAM-1 expression
induced by S1P, HPMVECs were treated with S1P in
the presence of Y-27632, an inhibitor of Rho-kinase,
exoenzyme C3, an ADP-ribosyltransferase inactivat-
ing Rho, and GGTI-286, an inhibitor of geranylger-
anyl transferase-I (GGTase-I) which inhibits the acti-
vation of Rho by preventing the prenylation of these
proteins and their translocations to membrane. Y-
27632, exoenzyme C3, and GGTI-286 were added to
the cells, 30 min prior to incubation with S1P. For the
experiments using exoenzyme C3, cell permeabiliza-
tion with streptolysin O was done according to previ-
ous reports.21 Moreover, active form of RhoA (GTP-
RhoA) was measured before and after exposure to
S1P using the Rhotekin binding domain assay. To de-
termine involvement of Gi, an inhibitory G protein of
adenyl cyclase, in the effects of S1P on these adhe-
sion molecules, HPMVECs were treated with PTX,
which catalyzes the ADP-ribosylation of the regula-
tory subunits of Gi protein, for 4 h prior to incubation
with S1P. To determine whether S1P causes adhe-
sion of eosinophils to endothelium, the number of ad-
herent EoL-1 cells was measured after stimulation of
HPMVECs with S1P for 8 h. To determine involve-
ment of RhoARho-kinase and Gi in adherence of
EoL-1 cells to endothelial cells, the number of adher-
ent EoL-1 cells was calculated after HPMVECs were
treated with S1P, treated with S1P in the presence of
Y-27632, and treated with S1P subsequent to incuba-
tion with PTX. Time-matched control cells were
treated similarly to test cells, but were exposed to the
serum-free medium (control) in the absence of S1P,
Y-27632, exoenzyme C3, GGTI-286, and PTX.
REAGENTS
S1P was obtained from BIOMOL (Plymouth Meet-
ing, PA, USA). PTX was obtained from Sigma (St.
Louis, MO, USA). Y-27632 was obtained from Wako
(Osaka, Japan). GGTI-286 and NSC23766 were ob-
tained from EMD Biosciences (San Diego, CA, USA).
C3 exoenzyme was obtained from List Biological
Laboratories, Incorporated (Campbell, CA, USA).
STATISTICAL ANALYSIS
All of the experiments were performed in triplicate.
The results of multiple observations are presented as
mean ± S.D., and compared using analysis of variance
followed by Bonferroni-Dunn post hoc test. P < 0.05
was considered to be a significant difference.
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Fig.　1　Involvement of S1P in the expression of adhesion molecules in HPMVECs. mRNA (A) and 
protein (B) expression of adhesion molecules (VCAM-1, ICAM-1) were increased in S1P-treated HP-
MVECs in a concentration-dependent manner. The expression of GAPDH was used to normalize the 
expression of adhesion molecules in RT-PCR analysis. In histograms, data were shown by the rela-
tive expression compared with the expression in control. -, control. *P < 0.05 vs control.
VCAM-1 ICAM-1
R
el
at
iv
e 
fo
ld
R
el
at
iv
e 
fo
ld
VCAM-1
GAPDH
ICAM-1
GAPDH
-
R
el
at
iv
e 
fo
ld
R
el
at
iv
e 
fo
ld
S1P
S1P
VCAM-1 ICAM-1
A
B
5
0
5
0
5
0
5
0
* **
***
**
* *
(PM)
(PM)
(PM)
(PM)
0.1 0.5 1 5 10-
- 0.1 0.5 1 5 10
*
0.1 0.5 1 5 10
10510.50.1-
RESULTS
ROLE OF S1P IN EXPRESSION OF ADHESION
MOLECULES IN HPMVECs
The expression of VCAM-1 and ICAM-1 was exam-
ined by RT-PCR in HPMVECs incubated with S1P be-
tween 0.1 and 10 μM for 4 h, and was examined by
Western blotting analysis in HPMVECs with S1P at
equi-molars incubated for 8 h. Exposure to S1P mark-
edly upregulated both the mRNA and protein expres-
sion of VCAM-1 in a concentration-dependent manner
(Fig. 1A, B). S1P (>1 μM) increased the mRNA and
protein expression of VCAM-1 by 4.5 ± 0.8 (n = 3, P <
0.05) and 4.7 ± 0.7 (n = 3, P < 0.05) fold, respectively.
S1P also upregulated these expression of ICAM-1 in a
concentration-dependent manner (Fig. 1A, B). S1P
(>1 μM) increased these expression of ICAM-1 by 1.9
± 0.2 (n = 3, P < 0.05) and 1.8 ± 0.2 (n = 3, P < 0.05)
fold, respectively.
Next, the mRNA and protein expression of VCAM-
1 in HPMVECs were examined after incubation with
10 μM S1P for up to 24 h. The mRNA expression of
VCAM-1 was maximally increased at 4 h after applica-
tion of S1P, but when the treatment with S1P was pro-
longed, the expression was decreased (Fig. 2A). In
contrast, the protein expression of VCAM-1 in re-
sponse to S1P was maximally increased at 8 h after
application of S1P (Fig. 2B).
ROLE OF S1P IN ACTIVATION OF RhoA
After HPMVECs were exposed to serum-free me-
dium in the absence (control) and presence of 10 μM
S1P for 10 min, relative proportion of GTP-RhoA to to-
tal RhoA (GTP-RhoAtotal RhoA) was measured us-
ing the Rhotekin binding domain assay. The values of
GTP-RhoAtotal RhoA was increased to 3.2 ± 0.4 fold
(n = 3, P < 0.05) by application of 10 μM S1P, com-
pared with the control (Fig. 3).
ROLE OF THE RhoA SIGNAL TRANSDUCTION
PATHWAY IN S1P-INDUCED EXPRESSION OF
ADHESION MOLECULES IN HPMVECs
Involvement of RhoA
When HPMVECs were exposed to 10 μM S1P in the
presence of exoenzyme C3 (10-30 ngml), levels of
mRNA and protein expression in VCAM-1 were also
attenuated by exoenzyme C3 in a concentration-
dependent manner. Exoenzyme C3 (30 ngml) de-
creased the values of relative fold of mRNA and pro-
tein expression in VCAM-1 to 1.4 ± 0.2 (n = 3, P <
0.05) and 1.6 ± 0.4 (n = 3, P < 0.05) fold, respectively
(Fig. 4A, B).
Adhesion Molecules Induced by S1P
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Fig.　2　Time-dependent effects of S1P on the expression of adhesion molecules in HPMVECs. 
mRNA (A) and protein (B) expression of VCAM-1 were increased in 10 μM S1P-treated HPMVECs in 
a time-dependent manner. The expression of GAPDH was used to normalize the expression of adhe-
sion molecules in RT-PCR analysis.  In histograms, data were expressed as shown in Figure 1. 
*P < 0.05 vs control.
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Fig.　3　Involvement of S1P in RhoA activity in HPMVECs. 
Activated forms of RhoA (GTP-RhoA) was pulled down from 
the cell lysates with Rhotekin-binding conjugated beads, and 
analyzed by Western blotting using anti-RhoA. The identical 
cell lysates were used to determine total RhoA (top trace). 
The value of GTP-RhoA/total RhoA induced by S1P was cal-
culated relative to that for control (bottom trace).  *P < 0.05 
vs control.
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Involvement of Geranylgeranyl Transferase-I
Furthermore, when HPMVECs were exposed to an
equi-molar of S1P in the presence of GGTI-286 (1-10
μM), levels of mRNA and protein expression in
VCAM-1 were attenuated by GGTI-286 in a
concentration-dependent manner. GGTI-286 (10 μM)
decreased the values of relative fold of mRNA and
protein expression in VCAM-1 to 1.9 ± 0.2 (n = 3, P <
0.05) and 1.7 ± 0.2 (n = 3, P < 0.05) fold, respectively
(Fig. 4C, D).
Involvement of Rho-kinase
Next, when HPMVECs were exposed to an equi-
molar of S1P in the presence of Y-27632 (0.1-10 μM),
levels of mRNA and protein expression in VCAM-1
were attenuated by Y-27632 in a concentration-
dependent manner. Y-27632 (10 μM) decreased the
values of relative fold of mRNA and protein expres-
sion in VCAM-1 to 1.8 ± 0.2 (n = 3, P < 0.05) and 1.2 ±
0.5 (n = 3, P < 0.05) fold, respectively (Fig. 5A, B).
ROLE OF Gi IN S1P-INDUCED EXPRESSION OF
ADHESION MOLECULES IN HPMVECs
HPMVECs were exposed to 10 μM S1P in the ab-
sence and presence of PTX (10-300 ngml) for 4 h.
Pre-treatment with PTX suppressed markedly the
augmented levels of mRNA and protein expression in
VCAM-1 induced by 10 μM S1P in a concentration-
dependent manner. After treatment with 300 ngml
PTX, the values of relative fold of mRNA and protein
expression in VCAM-1 were decreased to 1.9 ± 0.3 (n
= 3, P < 0.05) and 1.2 ± 0.3 (n = 3, P < 0.05) fold, re-
spectively (Fig. 6A, B).
EoL-1 CELLS ADHESION TO S1P-TREATED
HPMVECs
RT-PCR analysis demonstrated that VLA-4 and LFA-1
are expressed in EoL-1 cells (Fig. 7A). After EoL-1
cells were treated with the medium in the absence
and presence of S1P (1-10 μM) for 8 h, EoL-1 cells
were incubated with HPMVECs monolayers for 1 h.
Adherence of EoL-1 cells to HPMVECs was in-
creased by pre-exposure to S1P in a concentration-
dependent manner (Fig. 7B). S1P (10 μM) caused a
marked increase in the number of adherent cells
Sashio T et al.
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Fig.　4　Involvement of RhoA in the expression of adhesion molecules by S1P in HPMVECs. mRNA 
(A) and protein (B) expression of VCAM-1 after exposure to 10 μM S1P in the absence and presence 
of C3 exoenzyme (10-30 ng/ml). mRNA (C) and protein (D) expression of VCAM-1 after exposure to 
10 μM S1P in the absence and presence of GGTI-286 (1-10 μM). The expression of GAPDH was 
used to normalize the expression of adhesion molecules in RT-PCR analysis. In histograms, data 
were expressed as shown in Figure 1.  C3, C3 exoenzyme.  #P < 0.05 vs 10 μM S1P stimulation.
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from 0.6 (±0.1) × 105 to 1.4 (±0.3) × 105 (n = 4, P <
0.01) (Fig. 7C). When EoL-1 cells were treated with
10 μM S1P in the presence of 10 μM Y-27632, aug-
mented adherence of EoL-1 cells to HPMVECs by S1
P was markedly suppressed by Y-27632 (Fig. 7B). Y-
27632 decreased the number of adherent cells to 0.7
(±0.2) × 105 (n = 4, P < 0.01) (Fig. 7C). When EoL-1
cells were treated with 10 μM S1P subsequent to in-
cubation with 300 ngml PTX, adherence of EoL-1
cells to HPMVECs was also markedly suppressed
(Fig. 7B). PTX decreased the number of adherent
cells to 0.8 (±0.1)×105 (n = 4, P < 0.01) (Fig. 7C).
DISCUSSION
We have demonstrated for the first time that S1P in-
duces the expression of VCAM-1 in the endothelium
of human pulmonary vessels such as HPMVECs,
similar to human umbilical vein endothelial cells
(HUVECs).24,25 As shown in Figure 1, 2, after expo-
sure to S1P (>1 μM) for 4 h, the expression of VCAM-
1 was markedly enhanced, in contrast, an increase in
the expression of ICAM-1 induced by S1P was signifi-
cant, but not so drastic. Therefore, its response may
not be meaningful for the physiological effect.
It is generally considered that S1P is related to re-
cruitment of eosinophils to the airway wall mediated
by migration of cultured human eosinophils and
upregulation of CCR3, which is the fundamental
chemokine receptor involved in the eosinophil func-
tion.3 Since S1P augments expression of adhesion
molecules (mainly VCAM-1) in HPMVECs (Fig. 1, 2),
this present study demonstrate that S1P also acts on
not only chemotaxis but also the first step (adhesion
to endothelium) in the recruitment of eosinophils.
Adhesion Molecules Induced by S1P
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Fig.　5　Involvement of Rho-kinase in the expression of adhesion molecules by S1P in HPMVECs. 
mRNA (A) and protein (B) expression of VCAM-1 after exposure to 10 μM S1P in the absence and 
presence of Y-27632 (0.1-10 μM). The expression of GAPDH was used to normalize the expression 
of adhesion molecules in RT-PCR analysis. In histograms, data were expressed as shown in Figure 1. 
#P < 0.05 vs 10 μM S1P stimulation.
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Fig.　6　Involvement of Gi in the expression of adhesion molecules by S1P in HPMVECs. mRNA (A) 
and protein (B) expression of VCAM-1 after exposure to 10 μM S1P subsequent to incubation with 
the serum-free medium and PTX (10-300 ng/ml). The expression of GAPDH was used to normalize 
the expression of adhesion molecules in RT-PCR analysis. In histograms, data were expressed as 
shown in Figure 1.  #P < 0.05 vs 10 μM S1P stimulation.
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The maximal effect on expression of VCAM-1 was ob-
served 4-8 h after exposure to S1P (Fig. 2). This time
lag is roughly consistent with that lag which the late
asthmatic response occurs mediated by eosinophilic
inflammation after patients with asthma inhale aller-
gens. The concentrations of S1P in BAL are in-
creased from approximate 3 to 13 nM after allergen
challenges in patients with asthma.1 These observa-
tions indicate that S1P, which is released from mast
cells via the IgE-mediated allergic reaction,1,26 might
serve as a lipid mediator for the processes of infiltra-
tion of eosinophils to the airways implicated in this
disease.
To determine the mechanisms of pre-treatment
with S1P in expression of VCAM-1, involvement of
RhoA was examined in HPMVECs. As shown in Fig-
ure 3, S1P activates RhoA in HPMVECs, similar to
human airway smooth muscle cells.6 Furthermore, as
shown in Figure 4, 5, the expression of VCAM-1 in-
duced by S1P is attenuated by RhoA inhibitors such
as exoenzyme C3 and GGTI-286. These results indi-
cate that S1P upregurates VCAM-1 mediated by
Sashio T et al.
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Fig.　7　Involvement of S1P on EoL-1 cell adhesion to HPMVECs. (A) mRNA expression of LFA-1 and VLA-4 in EoL-1 cells. (B) 
Microphotograph of adherence of EoL-1 to HPMVECs treated with the serum-free medium (control), treated with S1P (1-10 
μM), treated with 10 μM S1P in the presence of 10 μM Y-27632, and treated with 10 μM S1P subsequent to incubation with 300 
ng/ml PTX. (C) The number of adhered EoL-1 cells to HPMVECs under each experimental condition shown in (B).  *P < 0.05 vs 
control.  #P < 0.05 vs 10 μM S1P stimulation.
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RhoA activation. Although exoenzyme C3 and GGTI-
286 may inhibit RhoA, RhoB, and RhoC nonselec-
tively, the effects of these agents are at least medi-
ated by RhoA in this study (Fig. 3). The three Rho
isoforms are structurally highly homologous, how-
ever have different effects on cell function.27 The fun-
damental roles of RhoA, RhoB, and RhoC are acto-
myosin contractility, cytokine trafficking and cell sur-
vival, and cell locomotion, respectively.
It is well known that the effector protein of RhoA is
Rho-kinase. Y-27632, a selective inhibitor of Rho-
kinase, inhibits an increase in expression of VCAM-1
induced by S1P in HPMVECs (Fig. 5). Therefore,
RhoARho-kinase processes contribute to this phe-
nomenon. Previous reports have shown that RhoA
Rho-kinase processes are involved in the expression
of VCAM-1 induced by UTP or ATP in coronary ar-
tery endothelial cells,28 and that these processes are
also involved in the expression of ICAM-1 induced by
thrombin in HUVECs.29 In HPMVECs, Y-27632 (<1
μM) did not significantly reduce the expression of
VCAM-1 induced by S1P (Fig. 5). The values of IC50
Adhesion Molecules Induced by S1P
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Fig.　8　The intracellular mechanisms underlying the upregulation of adhesion 
molecules induced by S1P. S1P acts on pulmonary endothelial cells as a lipid me-
diator. In the endothelium, the expression of VCAM-1 is markedly augmented via 
activation of Gi and RhoA, leading to enhancement of adherence of eosinophils. 
GGPP, geranylgeranylpyrophosphate.
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for the effects of Y-27632 on this adhesion molecule
were approximately 3 μM in HPMVECs (Data not
shown). 10 μM Y-27632 is also applied to suppress en-
hancement of VCAM-1 in coronary artery endothelial
cells,28 and HUVECs,29 respectively. On the other
hand, the Ki and IC50 values for Y-27632 for inhibiting
Rho-kinase are 0.1430 and 0.5 - 0.7 μM30,31 in smooth
muscle. S1P-induced contraction is completely sup-
pressed by 1 μM Y-27632 in guinea pig tracheal
smooth muscle.6 However, approximately 10 fold
higher concentrations of Y-27632 were needed to ob-
serve a marked inhibition in the expression of
VCAM-1 in vascular endothelial cells. This discrep-
ancy may be due to difference in species and tissues.
Next, we sought to determine signal transduction
pathways between S1P and RhoA in the upregulation
of VCAM-1. There are five specific receptors for S1P
(S1P1-5), which belong to a family of specific GTP
(G)-protein coupled receptors. These receptors are
able to couple to different G-proteins to elicit various
cellular responses.32 S1P-induced airway hyperre-
sponsiveness is attenuated by incubation of tracheal
tissues with 1000 ngml PTX for 6 h.6 A loss of Ca2+-
activated K+ channel activity by muscarinic stimula-
tion is reversed by incubation of tracheal smooth
muscle cells with 100 ngml PTX for 4 h.33 According
to the results shown in these previous reports,
HPMVECs were treated with 300 ngml PTX for 4 h
(Fig. 6). Since pre-treatment with PTX results in a
functional uncoupling of Gi, the inhibitory heterotrim-
eric G protein of adenylyl cyclase, from its associated
receptor via the ADP ribosylation, Gi may be involved
in the ability of S1P to elevate the levels of expression
of VCAM-1. Our results suggest that relationship be-
tween Gi and RhoA plays an essential role for this S1
P-induced action as the post-receptor signal transduc-
tion pathways (Fig. 8), similar to airway smooth mus-
cle cells.6 It is well known that effecter proteins of Gi
are Rac, a Rho family, and Ras, another monomeric G
protein.34 When HPMVECs were treated with S1P in
the presence of NSC23766, an inhibitor of Rac, the
ability of S1P to enhance the expression of VCAM-1
was not markedly reduced (Data not shown). Since
Ras stimulates mitogen-activated protein kinase,
HPMVECs were exposed to S1P in the presence of
PD98059, an inhibitor of mitogen-activated protein
kinase kinase. The effects of S1P on adhesion mole-
cules were also not significantly affected (Data not
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shown). Moreover, when HPMVECs were treated
with S1P in the presence of bisindolymaleimide, an
inhibitor of protein kinase C, the ability of S1P to en-
hance the expression of VCAM-1 was not markedly
reduced (Data not shown). Rac, Ras and protein
kinase C may not contribute to S1P-induced enhance-
ment of the expression of VCAM-1 in HPMVECs, dif-
ferent from results shown in previous reports using
HUVECs.35
Finally, we examined whether S1P, which causes
the expression of VCAM-1, leads to an increase in the
adherence of eosinophils to endothelial cells in pul-
monary vessels. Human blood eosinophils have a lim-
ited life-span, and purification of these cells from pa-
tients with asthma is not so easy because the percent-
ages of eosinophils are not always high in circulating
leucocytes. Hence, in this study, EoL-1, a human
eosinophilic leukemic cell line, was used to investi-
gate the adhesion of eosinophils in response to S1P in
vitro. In EoL-1 cells, pre-treatment with S1P increased
the number of adherent cells to the HPMVECs in a
concentration-dependent manner (Fig. 7B, C). Since
VLA-4 is expressed in the EoL-1 cells (Fig. 7A), these
results prove that S1P enhances adhesion of eosino-
phils to endothelial cells in pulmonary vessels via
upregulation of VCAM-1. Enhanced adherence of
EoL-1 cells by S1P was attenuated by Y-27632 and
PTX (Fig. 7B, C), supporting the idea that GiRhoA
Rho-kinase processes play a key role for this S1P-
induced adherence, although this signal transduction
pathway has never demonstrated in molecular bio-
logical technique.36
In conclusions, S1P may be involved in the eosino-
phil recruitment via enhancing adhesion to pulmo-
nary endothelial cells. This adhesive action is regu-
lated by the GiRhoARho-kinase processes in the
respiratory systems. Although clinical relevance of
these results may remain unknown, our observations
may provide that the Rho-kinase may be a therapeutic
target in the eosinophilic inflammation of asthma.37,38
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